Aaron Wealth Advisors LLC Has $407,000 Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Aaron Wealth Advisors LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 5,613 shares of the medical research company’s stock after selling 675 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after buying an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after buying an additional 126,194 shares in the last quarter. Norges Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $610,895,000. Finally, Brown Advisory Inc. raised its stake in shares of Edwards Lifesciences by 7.6% in the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company’s stock valued at $603,741,000 after buying an additional 575,699 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Dbs Bank upgraded shares of Edwards Lifesciences to a “hold” rating in a research note on Monday, June 2nd. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, May 16th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 13th. Finally, Citigroup reiterated a “buy” rating and set a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $80.20.

Edwards Lifesciences Stock Down 0.3%

Shares of NYSE:EW opened at $76.77 on Friday. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $95.25. The company’s 50-day moving average price is $76.10 and its two-hundred day moving average price is $73.26. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.03 billion, a P/E ratio of 10.97, a P/E/G ratio of 3.87 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.66 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the transaction, the vice president owned 47,206 shares of the company’s stock, valued at approximately $3,295,450.86. This trade represents a 16.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the transaction, the chief executive officer directly owned 58,284 shares in the company, valued at $4,366,054.44. This trade represents a 9.31% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,648 shares of company stock worth $2,998,866. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.